Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence Study of Bixalomer (AMG 223, ASP1585) Granule in Chronic Kidney Disease Patients with Hyperphosphataemia on Dialysis

Trial Profile

Bioequivalence Study of Bixalomer (AMG 223, ASP1585) Granule in Chronic Kidney Disease Patients with Hyperphosphataemia on Dialysis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bixalomer (Primary)
  • Indications Hyperphosphataemia
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 30 May 2014 New trial record
    • 12 May 2014 According to Astellas Pharma product pipeline list announced in May 2014, a bioequivalence study of a new formulation of bixalomer has been initiated in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top